Selamectin And Sarolaner

They govern key vital processes including nerve potential regulation, muscle contraction, locomotion and metabolic rhythm.From a species differentiation perspective, GluCls exist exclusively in invertebrates.Mammalian neuronal membranes lack this functional channel and only harbour structurally homologous yet functionally distinct chloride channel subtypes. Selamectin displays negligible binding affinity for mammalian homologous targets, which constitutes the core molecular basis for its high safety and low toxicity.Following topical administration on pet skin, selamectin slowly penetrates through lipid pathways in the stratum corneum into the dermis and systemic circulation.

Neuronal Interference and Parasite Lethal Process

Under physiological conditions in parasites, glutamate acts as a key excitatory neurotransmitter. Binding to neuronal membrane receptors precisely regulates GluCl gating, maintains ionic balance of chloride and sodium across the membrane, stabilizes resting membrane potential, and supports essential behaviours including muscle contraction, locomotion, host attachment, feeding and reproduction.Stable binding of selamectin to GluCls triggers sustained channel opening, breaks ionic homeostasis, and drives massive, continuous influx of extracellular chloride ions, inducing profound, irreversible hyperpolarization of parasite neuronal membranes.

Ultimately, parasites die from full nervous system paralysis and total physiological failure. Notably, this pharmacological cascade is irreversible. The drug–target complex exhibits extreme binding stability; parasite metabolic systems cannot dissociate the complex or repair impaired neuronal conduction, enabling thorough parasite elimination without post‑treatment parasite revival and guaranteeing sustained, complete deworming efficacy.

It efficiently kills adult worms while selectively inhibiting larval migration, development and moulting, interrupting the parasite growth and reproductive cycle within hosts.

In addition, it disturbs lipid metabolism and embryonic development in parasite eggs to suppress hatching, cutting off generative proliferation at the source and lowering risks of repeated and cross‑infestation in pets.For external parasite control: after topical application, a persistent drug reservoir forms on the pet skin surface, continuously acting on ear mites, sarcoptic mites, demodectic mites and other parasites residing on the epidermis and hair follicles.

Furthermore, its pharmacological action is mild and stable. Regular long‑term administration imposes no burden on the hepatic and renal metabolism of pets. Its target‑specific mode of action does not readily induce high‑frequency resistant mutations in parasites. A single topical dose maintains stable protection for 30 days, perfectly matching clinical requirements for monthly routine deworming. Selamectin serves as a fundamental core agent for comprehensive parasite control in companion animals.

This gene constitutes a key locus for parasite resistance mutations and the primary cause of failure of traditional antiparasitics.

Optimized via high‑throughput structural refinement, sarolaner's molecular architecture fits precisely the spatial structure of parasite GABA‑Cls, enabling accurate recognition and stable binding to channel proteins from both susceptible and resistant mutant strains.Species selectivity underpins its high safety profile: the subunit composition and spatial conformation of parasite GABA‑Cls differ drastically from mammalian counterparts.

Neuronal Hyperexcitation and Parasite Lethal Mechanism

In healthy arthropod parasites, γ‑aminobutyric acid functions as the major inhibitory neurotransmitter. Binding to neuronal GABA‑Cls facilitates chloride influx, restrains abnormal initiation and transmission of nerve impulses, stabilizes nervous system homeostasis, prevents excessive muscle excitation and spasms, and sustains normal parasitic behaviours including attachment, blood feeding and migration.Upon entering the parasite body, sarolaner competitively and irreversibly binds to receptor sites on GABA‑Cls, fully obstructing binding of endogenous GABA and shutting down chloride influx, thereby disrupting parasite neuronal ionic homeostasis.

Parasites quickly lose vital functions such as attachment, blood feeding and respiration and succumb to exhaustion.In contrast to selamectin, which induces gradual death via neuronal paralysis, sarolaner exerts faster onset of lethal action through neuronal hyperexcitation and higher pharmacodynamic potency. It eliminates most adult and larval fleas and ticks within 24 hours post‑administration, rapidly halting bite‑induced damage and relieving clinical signs including pruritus, erythema and skin ulceration in pets, demonstrating prominent advantages in emergency clinical intervention and parasite elimination.

A single administration maintains therapeutically effective parasiticidal concentrations for more than 30 days, continuously eliminating newly acquired and newly hatched parasites throughout this period to achieve persistent protection.

Against globally prevalent multi-resistant flea and tick populations encountered in companion animal practice, sarolaner exhibits no cross-resistance with traditional antiparasitics such as avermectins, pyrethroids and organophosphates, owing to its distinct molecular target. It effectively eradicates resistant parasite infections unresponsive to conventional treatments and addresses clinical challenges including treatment failure and recurrent infestations.

For clinical use, combination products containing selamectin and sarolaner integrate sarolaner's strengths of potent ectoparasitic activity and anti-resistance performance with selamectin's broad-spectrum endoparasitic efficacy. The two active ingredients act on independent targets and produce synergistic pharmacological effects, effectively overcoming the limitations of single-agent therapy. These formulations enable comprehensive control of all major internal and external parasites in dogs and cats, representing a core combination antiparasitic product balancing safety, broad-spectrum activity and efficacy in the current field of companion animal parasite management.